Neuropsychiatric Symptoms of Major or Mild Neurocognitive Disorders

  • Amer M. Burhan
  • Calvin H. Hirsch
  • Nicole E. Marlatt


Neuropsychiatric symptoms (NPS), or behavioral and psychological symptoms of dementia (BPSD), affect most individuals with major or mild neurocognitive disorders (NCDs), formerly termed dementia and mild cognitive impairment, at some point during the course of the illness. The near universal prevalence of NPS in NCDs has prompted the recent inclusion of non-cognitive symptoms in the core diagnostic criteria of NCDs. They are associated with a reduced quality of life and increased institutionalization, with adverse effects on both the patient and the formal and informal caregivers. Despite the prevalence of NPS, there are very few effective and safe pharmacological treatments available, partly based on the limited understanding of the underlying neurobiology of NPS. This chapter will provide a concise overview of non-cognitive symptoms of NCDs including the nature, prevalence, assessment, and management of these behaviors.


Neuropsychiatric symptoms (NPS) Behavioral and psychological symptoms of dementia (BPSD) Management Neurocognitive disorders (NCDs) 


  1. 1.
    Alzheimers Disease International. Dementia statistics: numbers of people with dementia 2010; December 31, 2016. Available from:
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders : DSM-5, vol. xliv. 5th ed. Arlington: American Psychiatric Association; 2013. p. 947.CrossRefGoogle Scholar
  3. 3.
    Sachs-Ericsson N, Blazer DG. The new DSM-5 diagnosis of mild neurocognitive disorder and its relation to research in mild cognitive impairment. Aging Ment Health. 2015;19(1):2–12.PubMedCrossRefGoogle Scholar
  4. 4.
    Karttunen K, Karppi P, Hiltunen A, Vanhanen M, Valimaki T, Martikainen J, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry. 2011;26(5):473–82.PubMedCrossRefGoogle Scholar
  5. 5.
    Rabins PV, Schwartz S, Black BS, Corcoran C, Fauth E, Mielke M, et al. Predictors of progression to severe Alzheimer’s disease in an incidence sample. Alzheimers Dement. 2013;9(2):204–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM. Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J Am Geriatr Soc. 2011;59(3):473–81.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Chan DC, Kasper JD, Black BS, Rabins PV. Presence of behavioral and psychological symptoms predicts nursing home placement in community-dwelling elders with cognitive impairment in univariate but not multivariate analysis. J Gerontol A Biol Sci Med Sci. 2003;58(6):548–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;169(9):946–53.PubMedCrossRefGoogle Scholar
  9. 9.
    Brodaty H, Draper B, Low LF. Nursing home staff attitudes towards residents with dementia: strain and satisfaction with work. J Adv Nurs. 2003;44(6):583–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Deutsch LH, Bylsma FW, Rovner BW, Steele C, Folstein MF. Psychosis and physical aggression in probable Alzheimer’s disease. Am J Psychiatry. 1991;148(9):1159–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Rovner BW, Kafonek S, Filipp L, Lucas MJ, Folstein MF. Prevalence of mental illness in a community nursing home. Am J Psychiatry. 1986;143(11):1446–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Malone ML, Thompson L, Goodwin JS. Aggressive behaviors among the institutionalized elderly. J Am Geriatr Soc. 1993;41(8):853–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Aronson MK, Post DC, Guastadisegni P. Dementia, agitation, and care in the nursing home. J Am Geriatr Soc. 1993;41(5):507–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996;8(Suppl 3):497–500.PubMedGoogle Scholar
  15. 15.
    Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–9.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry. 2011;26(4):364–72.PubMedCrossRefGoogle Scholar
  17. 17.
    McShane R. What are the syndromes of behavioral and psychological symptoms of dementia? Int Psychologeriatr. 2000;12:147–53.CrossRefGoogle Scholar
  18. 18.
    Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol. 1989;44(3):M77–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Geda YE, Schneider LS, Gitlin LN, Miller DS, Smith GS, Bell J, et al. Neuropsychiatric symptoms in Alzheimer’s disease: past progress and anticipation of the future. Alzheimers Dement. 2013;9(5):602–8.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015;314(12):1242–54.PubMedCrossRefGoogle Scholar
  21. 21.
    Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38(2):143–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–14.PubMedCrossRefGoogle Scholar
  23. 23.
    Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 Suppl 6):S10–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Cohen-Mansfield J. Agitation in the elderly. Adv Psychosom Med. 1989;19:101–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Finkel S, Rogers S. A clinical collaboration of a psychiatrist and a geriatric care manager. J Case Manag. 1992;1(2):49–52, 65.PubMedGoogle Scholar
  26. 26.
    Reisberg B, Monteiro I, Torossian C, Auer S, Shulman MB, Ghimire S, et al. The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review. Dement Geriatr Cogn Disord. 2014;38(1–2):89–146.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Auer SR, Monteiro IM, Reisberg B. The empirical behavioral pathology in Alzheimer’s disease (E-BEHAVE-AD) rating scale. Int Psychogeriatr. 1996;8(2):247–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Levin HS, High WM, Goethe KE, Sisson RA, Overall JE, Rhoades HM, et al. The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry. 1987;50(2):183–93.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. A comparison of psychiatric symptoms in vascular dementia and Alzheimer’s disease. Am J Psychiatry. 1993;150(12):1806–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL. Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale. J Am Geriatr Soc. 1992;40(6):549–55.PubMedCrossRefGoogle Scholar
  31. 31.
    Starkstein SE, Ingram L, Garau ML, Mizrahi R. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry. 2005;76(8):1070–4.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry. 1988;23(3):271–84.PubMedCrossRefGoogle Scholar
  33. 33.
    Lueken U, Seidl U, Volker L, Schweiger E, Kruse A, Schroder J. Development of a short version of the Apathy Evaluation Scale specifically adapted for demented nursing home residents. Am J Geriatr Psychiatry. 2007;15(5):376–85.PubMedCrossRefGoogle Scholar
  34. 34.
    Ismail Z, Emeremni CA, Houck PR, Mazumdar S, Rosen J, Rajji TK, et al. A comparison of the E-BEHAVE-AD, NBRS, and NPI in quantifying clinical improvement in the treatment of agitation and psychosis associated with dementia. Am J Geriatr Psychiatry. 2013;21(1):78–87.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Devanand DP, Brockington CD, Moody BJ, Brown RP, Mayeux R, Endicott J, et al. Behavioral syndromes in Alzheimer’s disease. Int Psychogeriatr. 1992;4(Suppl 2):161–84.PubMedGoogle Scholar
  36. 36.
    Gauthier S, Cummings J, Ballard C, Brodaty H, Grossberg G, Robert P, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr. 2010;22(3):346–72.PubMedCrossRefGoogle Scholar
  37. 37.
    Zhao QF, Tan L, Wang HF, Jiang T, Tan MS, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.PubMedCrossRefGoogle Scholar
  38. 38.
    Aalten P, de Vugt ME, Lousberg R, Korten E, Jaspers N, Senden B, et al. Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory. Dement Geriatr Cogn Disord. 2003;15(2):99–105.PubMedCrossRefGoogle Scholar
  39. 39.
    Steinberg M, Shao H, Zandi P, Lyketsos CG, Welsh-Bohmer KA, Norton MC, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23(2):170–7.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288(12):1475–83.PubMedCrossRefGoogle Scholar
  41. 41.
    Chen JC, Borson S, Scanlan JM. Stage-specific prevalence of behavioral symptoms in Alzheimer’s disease in a multi-ethnic community sample. Am J Geriatr Psychiatry. 2000;8(2):123–33.PubMedCrossRefGoogle Scholar
  42. 42.
    Seitz D, Purandare N, Conn D. Prevalence of psychiatric disorders among older adults in long-term care homes: a systematic review. Int Psychogeriatr. 2010;22(7):1025–39.PubMedCrossRefGoogle Scholar
  43. 43.
    Brodaty H, Draper B, Saab D, Low LF, Richards V, Paton H, et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry. 2001;16(5):504–12.PubMedCrossRefGoogle Scholar
  44. 44.
    Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708–14.PubMedCrossRefGoogle Scholar
  45. 45.
    Srikanth S, Nagaraja AV, Ratnavalli E. Neuropsychiatric symptoms in dementia-frequency, relationship to dementia severity and comparison in Alzheimer’s disease, vascular dementia and frontotemporal dementia. J Neurol Sci. 2005;236(1–2):43–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Kazui H, Yoshiyama K, Kanemoto H, Suzuki Y, Sato S, Hashimoto M, et al. Differences of behavioral and psychological symptoms of dementia in disease severity in four major dementias. PLoS One. 2016;11(8):e0161092.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Chiu PY, Liu CH, Tsai CH. Neuropsychiatric manifestations in vascular cognitive impairment patients with and without dementia. Acta Neurol Taiwanica. 2007;16(2):86–91.Google Scholar
  48. 48.
    Staekenborg SS, Su T, van Straaten EC, Lane R, Scheltens P, Barkhof F, et al. Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. J Neurol Neurosurg Psychiatry. 2010;81(5):547–51.PubMedCrossRefGoogle Scholar
  49. 49.
    Fuh JL, Wang SJ, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer’s disease and vascular dementia. J Neurol Neurosurg Psychiatry. 2005;76(10):1337–41.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Hsieh CJ, Chang CC, Lin CC. Neuropsychiatric profiles of patients with Alzheimer’s disease and vascular dementia in Taiwan. Int J Geriatr Psychiatry. 2009;24(6):570–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Caputo M, Monastero R, Mariani E, Santucci A, Mangialasche F, Camarda R, et al. Neuropsychiatric symptoms in 921 elderly subjects with dementia: a comparison between vascular and neurodegenerative types. Acta Psychiatr Scand. 2008;117(6):455–64.PubMedCrossRefGoogle Scholar
  52. 52.
    Chiu PY, Tsai CT, Chen PK, Chen WJ, Lai TJ. Neuropsychiatric symptoms in Parkinson’s disease dementia are more similar to Alzheimer’s disease than dementia with Lewy bodies: a case-control study. PLoS One. 2016;11(4):e0153989.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord. 2004;19(1):60–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Ballard CG, Shaw F, Lowery K, McKeith I, Kenny R. The prevalence, assessment and associations of falls in dementia with Lewy bodies and Alzheimer’s disease. Dement Geriatr Cogn Disord. 1999;10(2):97–103.PubMedCrossRefGoogle Scholar
  55. 55.
    Aarsland D, Cummings JL, Larsen JP. Neuropsychiatric differences between Parkinson’s disease with dementia and Alzheimer’s disease. Int J Geriatr Psychiatry. 2001;16(2):184–91.PubMedCrossRefGoogle Scholar
  56. 56.
    Grossman M. Frontotemporal dementia: a review. J Int Neuropsychol Soc. 2002;8(4):566–83.PubMedCrossRefGoogle Scholar
  57. 57.
    Ratnavalli E, Brayne C, Dawson K, Hodges JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615–21.PubMedCrossRefGoogle Scholar
  58. 58.
    Banks SJ, Weintraub S. Neuropsychiatric symptoms in behavioral variant frontotemporal dementia and primary progressive aphasia. J Geriatr Psychiatry Neurol. 2008;21(2):133–41.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Mesulam MM. Primary progressive aphasia—differentiation from Alzheimer’s disease. Ann Neurol. 1987;22(4):533–4.PubMedCrossRefGoogle Scholar
  60. 60.
    Barber R, Snowden JS, Craufurd D. Frontotemporal dementia and Alzheimer’s disease: retrospective differentiation using information from informants. J Neurol Neurosurg Psychiatry. 1995;59(1):61–70.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Levy ML, Miller BL, Cummings JL, Fairbanks LA, Craig A. Alzheimer disease and frontotemporal dementias. Behavioral distinctions. Arch Neurol. 1996;53(7):687–90.PubMedCrossRefGoogle Scholar
  62. 62.
    Cohen-Mansfield J. Nonpharmacological management of behavioral problems in persons with dementia: the TREA model. Alzheim Care Q. 2000;1(4):22–34.Google Scholar
  63. 63.
    Hall GR, Buckwalter KC. Progressively lowered stress threshold: a conceptual model for care of adults with Alzheimer’s disease. Arch Psychiatr Nurs. 1987;1(6):399–406.PubMedGoogle Scholar
  64. 64.
    Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001;9(4):361–81.PubMedCrossRefGoogle Scholar
  65. 65.
    Kitwood T. Person and process in dementia. Int J Geriatr Psychiatry. 1993;8:541–5.CrossRefGoogle Scholar
  66. 66.
    Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 2011;122(2):117–35.PubMedCrossRefGoogle Scholar
  67. 67.
    Halliday GM, McCann HL, Pamphlett R, Brooks WS, Creasey H, McCusker E, et al. Brain stem serotonin-synthesizing neurons in Alzheimer’s disease: a clinicopathological correlation. Acta Neuropathol. 1992;84(6):638–50.PubMedCrossRefGoogle Scholar
  68. 68.
    Mann DM, Yates PO. Serotonin nerve cells in Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 1983;46(1):96.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Sukonick DL, Pollock BG, Sweet RA, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPRS/L polymorphism and aggressive behavior in Alzheimer disease. Arch Neurol. 2001;58(9):1425–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, et al. The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr. 2001;13(4):401–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Pritchard AL, Pritchard CW, Bentham P, Lendon CL. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007;24(3):201–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004;61(8):1249–53.PubMedCrossRefGoogle Scholar
  73. 73.
    Rocchi A, Micheli D, Ceravolo R, Manca ML, Tognoni G, Siciliano G, et al. Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease. Genet Test. 2003;7(4):309–14.PubMedCrossRefGoogle Scholar
  74. 74.
    Ueki A, Ueno H, Sato N, Shinjo H, Morita Y. Serotonin transporter gene polymorphism and BPSD in mild Alzheimer’s disease. J Alzheimers Dis. 2007;12(3):245–53.PubMedCrossRefGoogle Scholar
  75. 75.
    Holmes C, Arranz M, Collier D, Powell J, Lovestone S. Depression in Alzheimer’s disease: the effect of serotonin receptor gene variation. Am J Med Genet B Neuropsychiatr Genet. 2003;119B(1):40–3.PubMedCrossRefGoogle Scholar
  76. 76.
    Micheli D, Bonvicini C, Rocchi A, Ceravolo R, Mancuso M, Tognoni G, et al. No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. J Alzheimers Dis. 2006;10(4):371–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Lai MK, Tsang SW, Francis PT, Esiri MM, Keene J, Hope T, et al. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. Brain Res. 2003;974(1–2):82–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Garcia-Alloza M, Hirst WD, Chen CP, Lasheras B, Francis PT, Ramirez MJ. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer’s disease. Neuropsychopharmacology. 2004;29(2):410–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Lanctot KL, Herrmann N, Mazzotta P. Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13(1):5–21.PubMedCrossRefGoogle Scholar
  80. 80.
    Lanctot KL, Herrmann N, Eryavec G, van Reekum R, Reed K, Naranjo CA. Central serotonergic activity is related to the aggressive behaviors of Alzheimer’s disease. Neuropsychopharmacology. 2002;27(4):646–54.PubMedGoogle Scholar
  81. 81.
    Lanctot KL, Herrmann N, van Reekum R, Eryavec G, Naranjo CA. Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer’s disease. Int J Geriatr Psychiatry. 2002;17(6):531–41.PubMedCrossRefGoogle Scholar
  82. 82.
    Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia. 2005;43(3):442–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Herrmann N, Lanctot KL, Khan LR. The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2004;16(3):261–76.PubMedCrossRefGoogle Scholar
  84. 84.
    Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT. Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry. 2002;51(5):407–16.PubMedCrossRefGoogle Scholar
  85. 85.
    Engelborghs S, Vloeberghs E, Le Bastard N, Van Buggenhout M, Marien P, Somers N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int. 2008;52(6):1052–60.PubMedCrossRefGoogle Scholar
  86. 86.
    Tanaka Y, Meguro K, Yamaguchi S, Ishii H, Watanuki S, Funaki Y, et al. Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer’s disease. Ann Nucl Med. 2003;17(7):567–73.PubMedCrossRefGoogle Scholar
  87. 87.
    Lanctot KL, Herrmann N, Rothenburg L, Eryavec G. Behavioral correlates of GABAergic disruption in Alzheimer’s disease. Int Psychogeriatr. 2007;19(1):151–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Garcia-Alloza M, Tsang SW, Gil-Bea FJ, Francis PT, Lai MK, Marcos B, et al. Involvement of the GABAergic system in depressive symptoms of Alzheimer’s disease. Neurobiol Aging. 2006;27(8):1110–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, et al. Ways toward an early diagnosis in Alzheimer’s disease: the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005;1(1):55–66.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9(5):e111–94.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Fischer CE, Ting WK, Millikin CP, Ismail Z, Schweizer TA, Alzheimer Disease Neuroimaging I. Gray matter atrophy in patients with mild cognitive impairment/Alzheimer’s disease over the course of developing delusions. Int J Geriatr Psychiatry. 2016;31(1):76–82.PubMedCrossRefGoogle Scholar
  92. 92.
    Ting WK, Fischer CE, Millikin CP, Ismail Z, Chow TW, Schweizer TA. Grey matter atrophy in mild cognitive impairment/early Alzheimer disease associated with delusions: a voxel-based morphometry study. Curr Alzheimer Res. 2015;12(2):165–72.PubMedCrossRefGoogle Scholar
  93. 93.
    Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, et al. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2014;29(2):159–65.PubMedCrossRefGoogle Scholar
  94. 94.
    Bruen PD, McGeown WJ, Shanks MF, Venneri A. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain. 2008;131(Pt 9):2455–63.PubMedCrossRefGoogle Scholar
  95. 95.
    Ismail Z, Nguyen MQ, Fischer CE, Schweizer TA, Mulsant BH. Neuroimaging of delusions in Alzheimer’s disease. Psychiatry Res. 2012;202(2):89–95.PubMedCrossRefGoogle Scholar
  96. 96.
    Blanc F, Noblet V, Philippi N, Cretin B, Foucher J, Armspach JP, et al. Right anterior insula: core region of hallucinations in cognitive neurodegenerative diseases. PLoS One. 2014;9(12):e114774.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Donovan NJ, Wadsworth LP, Lorius N, Locascio JJ, Rentz DM, Johnson KA, et al. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum. Am J Geriatr Psychiatry. 2014;22(11):1168–79.PubMedCrossRefGoogle Scholar
  98. 98.
    Balthazar ML, Pereira FR, Lopes TM, da Silva EL, Coan AC, Campos BM, et al. Neuropsychiatric symptoms in Alzheimer’s disease are related to functional connectivity alterations in the salience network. Hum Brain Mapp. 2014;35(4):1237–46.PubMedCrossRefGoogle Scholar
  99. 99.
    Rosenberg PB, Nowrangi MA, Lyketsos CG. Neuropsychiatric symptoms in Alzheimer’s disease: what might be associated brain circuits? Mol Asp Med. 2015;43-44:25–37.CrossRefGoogle Scholar
  100. 100.
    Levy-Cooperman N, Burhan AM, Rafi-Tari S, Kusano M, Ramirez J, Caldwell C, et al. Frontal lobe hypoperfusion and depressive symptoms in Alzheimer disease. J Psychiatry Neurosci. 2008;33(3):218–26.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Kataoka K, Hashimoto H, Kawabe J, Higashiyama S, Akiyama H, Shimada A, et al. Frontal hypoperfusion in depressed patients with dementia of Alzheimer type demonstrated on 3DSRT. Psychiatry Clin Neurosci. 2010;64(3):293–8.PubMedCrossRefGoogle Scholar
  102. 102.
    Akiyama H, Hashimoto H, Kawabe J, Higashiyama S, Kai T, Kataoka K, et al. The relationship between depressive symptoms and prefrontal hypoperfusion demonstrated by eZIS in patients with DAT. Neurosci Lett. 2008;441(3):328–31.PubMedCrossRefGoogle Scholar
  103. 103.
    Terada S, Oshima E, Sato S, Ikeda C, Nagao S, Hayashi S, et al. Depressive symptoms and regional cerebral blood flow in Alzheimer’s disease. Psychiatry Res. 2014;221(1):86–91.PubMedCrossRefGoogle Scholar
  104. 104.
    Holthoff VA, Beuthien-Baumann B, Kalbe E, Ludecke S, Lenz O, Zundorf G, et al. Regional cerebral metabolism in early Alzheimer’s disease with clinically significant apathy or depression. Biol Psychiatry. 2005;57(4):412–21.PubMedCrossRefGoogle Scholar
  105. 105.
    Kim HJ, Ye BS, Yoon CW, Cho H, Noh Y, Kim GH, et al. Effects of APOE epsilon4 on brain amyloid, lacunar infarcts, and white matter lesions: a study among patients with subcortical vascular cognitive impairment. Neurobiol Aging. 2013;34(11):2482–7.PubMedCrossRefGoogle Scholar
  106. 106.
    Murray PS, Kirkwood CM, Gray MC, Fish KN, Ikonomovic MD, Hamilton RL, et al. Hyperphosphorylated tau is elevated in Alzheimer’s disease with psychosis. J Alzheimers Dis. 2014;39(4):759–73.PubMedPubMedCentralGoogle Scholar
  107. 107.
    Burhan AM, Marlatt NM, Palaniyappan L, Anazodo UC, Prato FS. Role of hybrid brain imaging in neuropsychiatric disorders. Diagnostics (Basel). 2015;5(4):577–614.CrossRefGoogle Scholar
  108. 108.
    Odenheimer G, Borson S, Sanders AE, Swain-Eng RJ, Kyomen HH, Tierney S, et al. Quality improvement in neurology: dementia management quality measures. Neurology. 2013;81(17):1545–9.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci. 2007;62(8):908–16.PubMedCrossRefGoogle Scholar
  110. 110.
    Kales HC, Gitlin LN, Lyketsos CG, Detroit Expert Panel on A, Management of Neuropsychiatric Symptoms of D. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. J Am Geriatr Soc. 2014;62(4):762–9.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008;179(8):787–93.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;3:CD007726.Google Scholar
  114. 114.
    Steinberg M, Tschanz JT, Corcoran C, Steffens DC, Norton MC, Lyketsos CG, et al. The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2004;19(1):19–26.PubMedCrossRefGoogle Scholar
  115. 115.
    Aalten P, de Vugt ME, Jaspers N, Jolles J, Verhey FR. The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry. 2005;20(6):523–30.PubMedCrossRefGoogle Scholar
  116. 116.
    Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990;113(12):941–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease. Cochrane Database Syst Rev. 2006;1:CD003476.Google Scholar
  118. 118.
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–43.PubMedCrossRefGoogle Scholar
  119. 119.
    Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005;353(22):2335–41.PubMedCrossRefGoogle Scholar
  120. 120.
    Brodaty H, Ames D, Snowdon J, Woodward M, Kirwan J, Clarnette R, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64(2):134–43.PubMedCrossRefGoogle Scholar
  121. 121.
    Seitz DP, Brisbin S, Herrmann N, Rapoport MJ, Wilson K, Gill SS, et al. Efficacy and feasibility of nonpharmacological interventions for neuropsychiatric symptoms of dementia in long term care: a systematic review. J Am Med Dir Assoc. 2012;13(6):503–6 e2.PubMedCrossRefGoogle Scholar
  122. 122.
    Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308(19):2020–9.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Scherder EJ, Bogen T, Eggermont LH, Hamers JP, Swaab DF. The more physical inactivity, the more agitation in dementia. Int Psychogeriatr. 2010;22(8):1203–8.PubMedCrossRefGoogle Scholar
  124. 124.
    Telenius EW, Engedal K, Bergland A. Long-term effects of a 12 weeks high-intensity functional exercise program on physical function and mental health in nursing home residents with dementia: a single blinded randomized controlled trial. BMC Geriatr. 2015;15:158.PubMedPubMedCentralCrossRefGoogle Scholar
  125. 125.
    Lowery D, Cerga-Pashoja A, Iliffe S, Thune-Boyle I, Griffin M, Lee J, et al. The effect of exercise on behavioural and psychological symptoms of dementia: the EVIDEM-E randomised controlled clinical trial. Int J Geriatr Psychiatry. 2014;29(8):819–27.PubMedCrossRefGoogle Scholar
  126. 126.
    Barreto Pde S, Demougeot L, Pillard F, Lapeyre-Mestre M, Rolland Y. Exercise training for managing behavioral and psychological symptoms in people with dementia: a systematic review and meta-analysis. Ageing Res Rev. 2015;24(Pt B):274–85.PubMedCrossRefGoogle Scholar
  127. 127.
    Brett L, Traynor V, Stapley P. Effects of physical exercise on health and well-being of individuals living with a dementia in nursing homes: a systematic review. J Am Med Dir Assoc. 2016;17(2):104–16.PubMedCrossRefGoogle Scholar
  128. 128.
    Shih YH, Pai MC, Huang YC, Wang JJ. Sundown syndrome, sleep quality, and walking among community-dwelling people with Alzheimer disease. J Am Med Dir Assoc. 2017;18:396.PubMedCrossRefGoogle Scholar
  129. 129.
    Oppikofer S, Geschwindner H. Nursing interventions in cases of agitation and dementia. Dementia (London). 2014;13(3):306–17.CrossRefGoogle Scholar
  130. 130.
    Douglas S, James I, Ballard C. Non-parmacological interventions in dementia. J Contin Prof Dev. 2004;10:171–7.Google Scholar
  131. 131.
    Malara A, De Biase GA, Bettarini F, Ceravolo F, Di Cello S, Garo M, et al. Pain assessment in elderly with behavioral and psychological symptoms of dementia. J Alzheimers Dis. 2016;50(4):1217–25.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Habiger TF, Flo E, Achterberg WP, Husebo BS. The interactive relationship between pain, psychosis, and agitation in people with dementia: results from a cluster-randomised clinical trial. Behav Neurol. 2016;2016:7036415.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Zwakhalen SM, Hamers JP, Abu-Saad HH, Berger MP. Pain in elderly people with severe dementia: a systematic review of behavioural pain assessment tools. BMC Geriatr. 2006;6:3.PubMedPubMedCentralCrossRefGoogle Scholar
  134. 134.
    Gitlin LN, Winter L, Dennis MP, Hodgson N, Hauck WW. Targeting and managing behavioral symptoms in individuals with dementia: a randomized trial of a nonpharmacological intervention. J Am Geriatr Soc. 2010;58(8):1465–74.PubMedPubMedCentralCrossRefGoogle Scholar
  135. 135.
    Belle SH, Burgio L, Burns R, Coon D, Czaja SJ, Gallagher-Thompson D, et al. Enhancing the quality of life of dementia caregivers from different ethnic or racial groups: a randomized, controlled trial. Ann Intern Med. 2006;145(10):727–38.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc. 1990;38(5):553–63.PubMedCrossRefGoogle Scholar
  137. 137.
    Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom. 2007;76(4):213–8.PubMedCrossRefGoogle Scholar
  138. 138.
    Ma H, Huang Y, Cong Z, Wang Y, Jiang W, Gao S, et al. The efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis. 2014;42(3):915–37.PubMedGoogle Scholar
  139. 139.
    Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer’s disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials. Int J Geriatr Psychiatry. 2007;22(5):475–84.PubMedCrossRefGoogle Scholar
  140. 140.
    Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14(3):191–210.PubMedCrossRefGoogle Scholar
  141. 141.
    Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355(15):1525–38.PubMedCrossRefGoogle Scholar
  142. 142.
    Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA. 2005;293(5):596–608.PubMedCrossRefGoogle Scholar
  143. 143.
    Lonergan E, Luxenberg J, Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev. 2002;(2):CD002852.Google Scholar
  144. 144.
    American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601.CrossRefGoogle Scholar
  145. 145.
    Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775–86.PubMedCrossRefGoogle Scholar
  146. 146.
    Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627–32.PubMedPubMedCentralCrossRefGoogle Scholar
  147. 147.
    Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry. 2012;169(1):71–9.PubMedCrossRefGoogle Scholar
  148. 148.
    Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151–7.PubMedCrossRefGoogle Scholar
  149. 149.
    Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;(2):CD008191.Google Scholar
  150. 150.
    Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682–91.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Schneider LS, Frangakis C, Drye LT, Devanand DP, Marano CM, Mintzer J, et al. Heterogeneity of treatment response to citalopram for patients with Alzheimer’s disease with aggression or agitation: the CitAD randomized clinical trial. Am J Psychiatry. 2016;173(5):465–72.PubMedCrossRefGoogle Scholar
  152. 152.
    Leonpacher AK, Peters ME, Drye LT, Makino KM, Newell JA, Devanand DP, et al. Effects of citalopram on neuropsychiatric symptoms in Alzheimer’s dementia: evidence from the CitAD study. Am J Psychiatry. 2016;173(5):473–80.PubMedCrossRefGoogle Scholar
  153. 153.
    Weintraub D, Drye LT, Porsteinsson AP, Rosenberg PB, Pollock BG, Devanand DP, et al. Time to response to citalopram treatment for agitation in Alzheimer disease. Am J Geriatr Psychiatry. 2015;23(11):1127–33.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Newell J, Yesavage JA, Taylor JL, Kraemer HC, Munro CA, Friedman L, et al. Sedation mediates part of Citalopram’s effect on agitation in Alzheimer’s disease. J Psychiatr Res. 2016;74:17–21.PubMedCrossRefGoogle Scholar
  155. 155.
    Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, et al. Citalopram for agitation in Alzheimer’s disease: design and methods. Alzheimers Dement. 2012;8(2):121–30.PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Rosenberg PB, Drye LT, Porsteinsson AP, Pollock BG, Devanand DP, Frangakis C, et al. Change in agitation in Alzheimer’s disease in the placebo arm of a nine-week controlled trial. Int Psychogeriatr. 2015;27(12):2059–67.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293–308.PubMedCrossRefGoogle Scholar
  158. 158.
    Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry. 1998;155(1):54–61.PubMedCrossRefGoogle Scholar
  159. 159.
    Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry. 2001;9(4):400–5.PubMedCrossRefGoogle Scholar
  160. 160.
    Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289(2):210–6.PubMedCrossRefGoogle Scholar
  161. 161.
    Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, et al. Donepezil for the treatment of agitation in Alzheimer’s disease. N Engl J Med. 2007;357(14):1382–92.PubMedCrossRefGoogle Scholar
  162. 162.
    Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;(3):CD006504.Google Scholar
  163. 163.
    Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537–45.PubMedCrossRefGoogle Scholar
  164. 164.
    Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341–8.PubMedCrossRefGoogle Scholar
  165. 165.
    Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, et al. Efficacy of memantine for agitation in Alzheimer’s dementia: a randomised double-blind placebo controlled trial. PLoS One. 2012;7(5):e35185.PubMedPubMedCentralCrossRefGoogle Scholar
  166. 166.
    Peisah C, Chan DK, McKay R, Kurrle SE, Reutens SG. Practical guidelines for the acute emergency sedation of the severely agitated older patient. Intern Med J. 2011;41(9):651–7.PubMedCrossRefGoogle Scholar
  167. 167.
    Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry. 2009;17(9):744–51.PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Vasudev A, Shariff SZ, Liu K, Burhan AM, Herrmann N, Leonard S, et al. Trends in psychotropic dispensing among older adults with dementia living in long-term care facilities: 2004–2013. Am J Geriatr Psychiatry. 2015;23(12):1259–69.PubMedCrossRefGoogle Scholar
  169. 169.
    Podsiadlo D, Richardson S. The timed “up & go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.PubMedCrossRefGoogle Scholar
  170. 170.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.PubMedCrossRefGoogle Scholar
  171. 171.
    Honore PM, Spapen HD. Cefepime-induced neurotoxicity in critically ill patients undergoing continuous renal replacement therapy: beware of dose reduction! Crit Care. 2015;19:455.PubMedPubMedCentralCrossRefGoogle Scholar
  172. 172.
    Pedroso JL, Nakama GY, Carneiro Filho M, Barsottini OG. Delirium, psychosis, and visual hallucinations induced by pregabalin. Arq Neuropsiquiatr. 2012;70(12):960–1.PubMedCrossRefGoogle Scholar
  173. 173.
    Vasudev A, Macritchie K, Vasudev K, Watson S, Geddes J, Young AH. Oxcarbazepine for acute affective episodes in bipolar disorder. Cochrane Database Syst Rev. 2017;(12):CD004857.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Amer M. Burhan
    • 1
  • Calvin H. Hirsch
    • 2
  • Nicole E. Marlatt
    • 3
  1. 1.Department of PsychiatryParkwood Institute-Mental Health/Western UniversityLondonCanada
  2. 2.Division of General MedicineUniversity of California Davis Medical CenterSacramentoUSA
  3. 3.Department of PsychiatrySt. Joseph’s Health Care London, Parkwood InstituteLondonCanada

Personalised recommendations